MedTrace Logo

Linezolid Plus Standard of Care

NCT06958835 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 606

Last updated 2026-03-24

No results posted yet for this study

Summary

The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.

Conditions

  • Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

Interventions

DRUG

Linezolid 600 mg

linezolid 600 mg tablets (twice a day for 5 days)

DRUG

Placebo

Placebo tablets (twice a day for 5 days)

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Richard Kühl, PD Dr. med. · University Hospital, Basel, Switzerland

  • Benjamin Speich, PD, PhD · University Hospital, Basel, Switzerland

  • Nina Khanna, Prof. Dr. med. · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-06
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06958835 on ClinicalTrials.gov